2 results
Approved WMOCompleted
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
Approved WMOCompleted
Primary objective:To assess the two-year prevalence and incidence of clinical relevant arrhythmias in drug-resistant epilepsy.Secondary objective:To assess whether the recorded cardiac arrhythmias are related to epileptic seizures (subjectively from…